- Home
- LNW vs JAZZ Comparison
LNW vs JAZZ Comparison
Compare LNW & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNW
- JAZZ
- Stock Information
- Founded
- LNW 1984
- JAZZ 2003
- Country
- LNW United States
- JAZZ Ireland
- Employees
- LNW N/A
- JAZZ N/A
- Industry
- LNW EDP Services
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- LNW Technology
- JAZZ Health Care
- Exchange
- LNW Nasdaq
- JAZZ Nasdaq
- Market Cap
- LNW 8.5B
- JAZZ 7.7B
- IPO Year
- LNW N/A
- JAZZ 2007
- Fundamental
- Price
- LNW $87.79
- JAZZ $128.02
- Analyst Decision
- LNW Buy
- JAZZ Strong Buy
- Analyst Count
- LNW 11
- JAZZ 14
- Target Price
- LNW $108.18
- JAZZ $178.93
- AVG Volume (30 Days)
- LNW 1.6M
- JAZZ 779.5K
- Earning Date
- LNW 08-06-2025
- JAZZ 08-05-2025
- Dividend Yield
- LNW N/A
- JAZZ N/A
- EPS Growth
- LNW 19.32
- JAZZ N/A
- EPS
- LNW 3.95
- JAZZ N/A
- Revenue
- LNW $3,195,000,000.00
- JAZZ $4,086,695,000.00
- Revenue This Year
- LNW $7.53
- JAZZ $5.65
- Revenue Next Year
- LNW $7.85
- JAZZ $5.79
- P/E Ratio
- LNW $22.03
- JAZZ N/A
- Revenue Growth
- LNW 3.83
- JAZZ 4.52
- 52 Week Low
- LNW $69.56
- JAZZ $95.49
- 52 Week High
- LNW $115.00
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- LNW 44.25
- JAZZ 65.56
- Support Level
- LNW $89.13
- JAZZ $122.50
- Resistance Level
- LNW $95.07
- JAZZ $117.21
- Average True Range (ATR)
- LNW 2.28
- JAZZ 2.85
- MACD
- LNW -0.18
- JAZZ 0.86
- Stochastic Oscillator
- LNW 28.73
- JAZZ 69.76
About LNW Light & Wonder Inc.
Light & Wonder is principally an electronic gaming machine manufacturer, selling machines to pubs, clubs, and casinos. The firm is licensed in most jurisdictions allowing gambling globally. Light & Wonder is one of the three largest players in the space along with International Game Technology and Aristocrat Leisure. SciPlay, about one fourth of revenue, develops and distributes casual mobile games, principally in the social casino niche. The more nascent iGaming business sits between these two businesses, providing digital content and capabilities to real-money gaming providers.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.